Many adjuvants are essential for cancer immunotherapy, such as aluminum salts (Awate et al., 2013), oil-in-water emulsions (Guy, 2007), low-toxicity QS-21 (Li and Li, 2020), toll-like receptor (TLR) agonist (Zhou et al., 2018), NKT-cell agonist (Li et al., 2022), stimulator of interferon gene (STING) (Van Herck et al., 2021), and other biological materials. Here, STING1 is linked to cancer.